Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection

Drug Development and Industrial Pharmacy

Volumn 38, Issue 5, 2012, Pages 540-549

  Chollet, John L ^a   Jozwiakowski, Michael J ^a  

^a Ther Rx Corporation   (United States)

Author keywords

compounding pharmacy; Hydroxyprogesterone caproate; injection; preterm birth

Indexed keywords

GLUCOSE; HYDROXYPROGESTERONE CAPROATE;

ARTICLE; CLINICAL ARTICLE; DRUG IMPURITY; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LABORATORY; QUALITY CONTROL; UNITED STATES;

DRUG APPROVAL; DRUG COMPOUNDING; FEMALE; HUMANS; HYDROXYPROGESTERONES; INJECTIONS; PREGNANCY; PREMATURE BIRTH; PROGESTINS; QUALITY CONTROL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84859353705     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.662511     Document Type: Article

References (34)

1. Ward RM, Beachy JC. (2004). Neonatal Complications Following Preterm Birth. Int J Obstet Gynecol, 110:8-16.
2. Iams JD, Berghella V. (2010). Care for women with prior preterm birth. Am J Obstet Gynecol, 203:89-100.
3. Tita AT, Rouse DJ. (2009). Progesterone for preterm birth prevention: an evolving intervention. Am J Obstet Gynecol, 200:219-224.
4. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH et al.; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. (2003). Prevention of recurrent preterm delivery by 17 alpha-ydroxyprogesterone caproate. N Engl J Med, 348:2379-2385. (Pubitemid 36682816)
5. American College of Obstetricians and Gynecologists. (2008). Use of Progesterone to Reduce Preterm Birth. ACOG Committee Opinion No. 419. Obstet Gynecol, 112:963-965.
6. Wing D, Powers B, Hickok D. (2010) U.S. Food and Drug Administration Drug Approval. Slow Advances in Obstetric Care in the United States. Obstet Gynecol, 115:825-833.
7. Reifenstein E. (1971) Hydroxyprogesterone Caproate Therapy in Advanced Endometrial Cancer. Cancer, 27:485-502.
8. United State Pharmacopeia 34 - National Formulary 29. The United States Pharmacopeial Convention, Rockville, MD. 2011.
9. U.S. Food and Drug Administration. The Special Risks of Pharmacy Compounding. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ ucm107836.htm Accessed on 15 April 2011.
10. Sasich LD, Sukkari SR. (2008). Unknown risks of pharmacy-ompounded drugs. J Am Osteopath Assoc, 108:86.
11. American College of Obstetricians and Gynecologists. Pharmaceutical Compounding. (2007). ACOG Committee Opinion No. 387. Obstet Gynecol, 110:1213-1214.
12. US Food and Drug Administration. Pharmacy Compounding. 2006 Limited FDA Survey of Compounded Drug Products. Available at: http://www.fda.gov/ Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm204237.htm. Accessed on 15 April 2011.
13. Missouri Board of Pharmacy Compounding Report. FY2006-2009. Accessed at: http://pr.mo.gov/pharmacists-ompounding.asp. Accessed April 2011.
14. Markman BE, Rosa PC, Koschtschak MR. (2010). Assessment of the quality of simvastatin capsules from compounding pharmacies. Rev Saude Publica, 44:1055-1062.
15. Green DM, Jones AC, Brain KR. (2011). Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. J Clin Pharm Ther, 1-6.
16. Azarnoff DL, Lee JC, Lee C, Chandler J, Karlin D. (2007). Quality of extemporaneously compounded nitroglycerin ointment. Dis Colon Rectum, 50:509-516. (Pubitemid 46701612)
17. Mahaguna V, McDermott JM, Zhang F, Ochoa F. (2004). Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel. Drug Dev Ind Pharm, 30:1069-1078. (Pubitemid 39577999)
18. Sunenshine R, Schultz M, Lawrence MG, Shin S, Jensen B, Zubairi S et al. (2009). An outbreak of postoperative gram-negative bacterial endophthalmitis associated with contaminated trypan blue ophthalmic solution. Clin Infect Dis, 48:1580-1583.
19. Suchard JR, Graeme KA. (2002). Pediatric clonidine poisoning as a result of pharmacy compounding error. Pediatr Emerg Care, 18:295-296.
20. Centers for Disease Control. (2007). Deaths from Intravenous Colchicine Resulting from a Compounding Pharmacy Error - Oregon and Washington, 2007. MMRW Morbid Mortal Wkly, 56:1050-1052.
21. Gershman MD, Kennedy DJ, Noble-Wang J, Kim C, Gullion J, Kacica M et al.; Pseudomonas fluorescens Investigation Team. (2008). Multistate outbreak of Pseudomonas fluorescens bloodstream infection after exposure to contaminated heparinized saline flush prepared by a compounding pharmacy. Clin Infect Dis, 47:1372-1379.
22. Schwam E. (2011). Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med, 41: 51-54.
23. Cohen AW, Copel JA, Macones GA, Menard MK, Riley L, Saade GR. (2011). Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17a-hydroxyprogesterone caproate). Obstet Gynecol, 117:1-3.
24. Bradshaw ST, Sampson K, Wesoloski BJ. (2011). The Food and Drug Law Institute. Did FDA Apply a Remedy Worse Than the Disease in Refusing to Clear the Market of Unapproved Versions of Makena? Food and Drug Policy Forum, 1:1-8.
25. Food and Drug Administration. FDA Statement on Makena. Available at: http://www.fda.gov/newsEvents/Newsroom/PressAnnouncements/ucm249025.htm. Accessed on 12 December 2011.
26. Food and Drug Administration. Impurities in New Drug Substances. June 2008, (International Committee on Harmonization, Revision 2).
27. Onsrud M, Paus E, Haug E, Kjorstad K. (1985). Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal function. Acta Obstet Gynecol Scand, 64: 519-523. (Pubitemid 15241030)
28. Liu H, Zhang Z, Linhardt RJ. (2009). Lessons learned from the contamination of heparin. Nat Prod Rep, 26:313-321.
29. Guan N, Fan Q, Ding J, Zhao Y, Lu J, Ai Y et al. (2009). Melamine-contaminated powdered formula and urolithiasis in young children. N Engl J Med, 360:1067-1074.
30. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 6th edition. Philadelphia: Lippincott Williams and Wilkins, 2002:xv-xix.
31. Kaye T. (2003). The quandary of compounding for MCOs: administrative costs, risks, and waste. Manag Care, 12:42-48.
32. Boodoo JM. Compounding Problems and Compounding Confusion: Federal Regulation of Compounded Drug Products and the FDMA Circuit Split. Am J Law Med, 2010:220:1-27.
33. ACOG and SMFM update position on 17P. Contemp Obgyn 2011; December 2011:13.
34. FDA Statement on Makena. US Food and Drug Administration, Silver Spring, MD. November 8, 2011.